インフラRxの適時開示

6-K 1 ef20079015_6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-38283

InflaRx N.V.

(Translation of registrant’s name into English)

Winzerlaer Str. 2

07745 Jena, Germany

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

Exhibits 99.1 and 99.2 to this report on Form 6-K (this “Report”) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Nos. 333-221656 and 333-240185) of InflaRx N.V. and to be a part thereof from the date on which this Report is submitted, in each case to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description

99.1	InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Three and Six Months Ended June 30, 2026
99.2	InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3	InflaRx N.V. Press Release dated August 6, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INFLARX N.V.

Date: August 6, 2026	By:	/s/ Niels Riedemann
	Name:	Niels Riedemann
	Title:	Chief Executive Officer

EX-99.1 2 ef20079015_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

INFLARX N.V.

UNAUDITED CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS – June 30, 2026

These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statements are presented in euros (€).

InflaRx N.V. is a company limited by shares, incorporated and domiciled in Amsterdam, The Netherlands.

Its registered office and principal place of business is in Germany, 07745 Jena, Winzerlaer Str. 2

Index to unaudited condensed consolidated financial statements

for the six months ended June 30, 2026

Unaudited condensed consolidated statements of operations and comprehensive loss for the three months and six months ended June 30, 2026 and 2025				3
Unaudited condensed consolidated statements of financial position as of June 30, 2026 and December 31, 2025				4
Unaudited condensed consolidated statements of changes in shareholders’ equity for the three months and six months ended June 30, 2026 and 2025				5
Unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025				6
Notes to the unaudited condensed consolidated financial statements				7
	1.		Summary of significant accounting policies and other disclosures	7
		a)	Reporting entity and the Group’s structure	7
		b)	Basis of preparation	7
	2.		Revenues	8
	3.		Cost of sales	8
	4.		Sales and marketing expenses	8
	5.		Research and development expenses	8
	6.		General and administrative expenses	8
	7.		Other income	8
	8.		Net financial result	9
	9.		Other assets	9
	10.		Tax receivables	10
	11.		Financial assets and financial liabilities	10
	12.		Trade payables and other accrued liabilities	11
	13.		Cash and cash equivalents	11
	14.		Equity	11
	15.		Share-based payments	12
		a)	Equity settled share-based payment arrangements	12
		b)	Share-based payment expense recognized	13
		c)	Share options exercised	13
	16.		Protective foundation	13

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of operations and comprehensive loss for the three months and six months ended June 30, 2026 and 2025

			For the three months ended June 30,						For the six months ended June 30,
	Note		2026 (unaudited)			2025 (unaudited)			2026 (unaudited)			2025 (unaudited)
			(in €, except for share data)

Revenues		2		—			39,432			—			39,432
Cost of sales		3		—			(2,399,583	)		—			(2,408,874	)
Gross profit (loss)				—			(2,360,151	)		—			(2,369,442	)
Sales and marketing expenses		4		(30,175	)		(1,013,347	)		(138,247	)		(2,471,326	)
Research and development expenses		5		(4,739,126	)		(7,202,942	)		(8,909,671	)		(14,219,279	)
General and administrative expenses		6		(2,548,319	)		(3,279,485	)		(5,725,763	)		(8,342,090	)
Other income		7		266,574			937,938			514,552			1,479,035
Other expenses				—			—			(66	)		(26	)
Operating result				(7,051,045	)		(12,917,988	)		(14,259,195	)		(25,923,127	)
Finance income		8		770,661			522,221			1,105,429			1,015,985
Finance expenses		8		(14,643	)		(3,355	)		(29,452	)		(7,441	)
Foreign exchange result		8		3,558,919			(2,869,983	)		4,051,301			(4,778,812	)
Other financial result		8		(7,912,375	)		852,834			(7,109,214	)		6,963,097
Income taxes				—			—			—			—
Income (loss) for the period				(10,648,484	)		(14,416,271	)		(16,241,132	)		(22,730,298	)
Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign currency				(19,274	)		(113,604	)		(34,301	)		(264,271	)
Total comprehensive income (loss)				(10,667,758	)		(14,529,876	)		(16,275,433	)		(22,994,569	)

Share information
Weighted average number of shares outstanding				117,663,937			67,747,130			95,103,732			65,542,269
Income (loss) per share (basic/diluted)				(0.09	)		(0.21	)		(0.17	)		(0.35	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-3

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of financial position as of June 30, 2026 and December 31, 2025

	Note		June 30, 2026 (unaudited)			December 31, 2025
			(in €)
ASSETS
Non-current assets
Property and equipment				267,714			289,317
Right-of-use assets				802,608			861,667
Intangible assets				78,123			42,255
Other assets		9		126,201			151,198
Financial assets		11		237,020			237,373
Total non-current assets				1,511,667			1,581,810
Current assets
Current other assets		9		2,331,968			3,261,038
Other assets from government grants and research allowance		9		2,997,282			2,487,763
Tax receivables		10		1,551,922			1,428,428
Financial assets		11		11,946,598			30,435,088
Cash and cash equivalents		13		146,567,894			16,022,171
Total current assets				165,395,665			53,634,487
TOTAL ASSETS				166,907,332			55,216,297

EQUITY AND LIABILITIES
Equity
Issued capital		14		17,684,187			8,675,143
Share premium				465,336,467			354,975,760
Other capital reserves				50,092,973			48,560,500
Accumulated deficit				(394,067,134	)		(377,826,001	)
Other components of equity				7,137,079			7,171,379
Total equity				146,183,572			41,556,781
Non-current liabilities
Lease liabilities				560,494			640,973
Other liabilities		12		36,877			36,877
Total non-current liabilities				597,371			677,850
Current liabilities
Trade and other payables		11		5,303,862			5,399,383
Lease liabilities				272,685			256,943
Employee benefits				907,425			1,164,259
Liabilities to warrant holders				13,270,142			5,802,128
Other liabilities		12		372,275			358,954
Total current liabilities				20,126,389			12,981,666
Total Liabilities				20,723,760			13,659,516
TOTAL EQUITY AND LIABILITIES				166,907,332			55,216,297

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-4

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of changes in shareholders’ equity for the six months ended June 30, 2026 and 2025

(in €, except for share data)	Note		Shares outstanding		Issued capital		Share premium			Other capital reserves		Accumulated deficit			Other compo- nents of equity			Total equity

Balance as of January 1, 2026				72,292,859		8,675,143		354,975,760			48,560,500		(377,826,001	)		7,171,379			41,556,781
Loss for the period				—		—		—			—		(16,241,132	)		—			(16,241,132	)
Exchange differences on translation of foreign currency				—		—		—			—		—			(34,301	)		(34,301	)
Total comprehensive loss				—		—		—			—		(16,241,132	)		(34,301	)		(16,275,433	)
Issuance of ordinary shares				75,000,000		9,000,000		118,442,651			—		—			—			127,442,651
Transaction costs for ordinary shares				—		—		(8,185,666	)		—		—			—			(8,185,666	)
Equity-settled share-based payments		15		—		—		—			1,532,473		—			—			1,532,473
Share options exercised				75,362		9,043		103,722			—		—			—			112,766
Balance as of June 30, 2026				147,368,221		17,684,186		465,336,467			50,092,973		(394,067,133	)		7,137,078			146,183,572

Balance as of January 1, 2025				59,351,710		7,122,205		334,929,685			44,115,861		(332,192,221	)		7,440,510			61,416,039
Loss for the period				—		—		—			—		(22,730,298	)		—			(22,730,298	)
Exchange differences on translation of foreign currency				—		—		—			—		—			(264,271	)		(264,271	)
Total comprehensive loss				—		—		—			—		(22,730,298	)		(264,271	)		(22,994,569	)
Issuance of common shares				8,395,420		1,007,450		15,136,235			—		—			—			16,143,686
Transaction costs				—		—		(1,109,305	)		—		—			—			(1,109,305	)
Equity-settled share-based payments		15		—		—		—			3,588,514		—			—			3,588,514
Balance as of June 30, 2025				67,747,130		8,129,656		348,956,615			47,704,375		(354,922,519	)		7,176,239			57,044,364

*unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-5

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025

			For the six months ended June 30,
	Note		2026 (unaudited)			2025 (unaudited)
			(in €)
Operating activities
Loss for the period				(16,241,132	)		(22,730,298	)
Adjustments for:
Depreciation & amortization of property and equipment, right-of-use assets and intangible assets				179,263			228,801
Net finance income		8		1,981,937			(3,192,828	)
Share-based payment expense		15		1,532,473			3,588,514
Net foreign exchange differences and other adjustments				1,621,940			1,518,421
Changes in:
Other assets from government grants and research allowances				(509,519	)		(782,175	)
Other assets and trade receivables		9		830,572			(408,339	)
Employee benefits				(256,834	)		(950,043	)
Other liabilities		12		13,321			60,068
Trade and other payables		12		(95,521	)		(1,658,576	)
Inventories				—			1,859,251
Interest received		8		1,009,374			906,087
Interest paid				(30,100	)		(7,652	)
Net cash used in operating activities				(9,964,225	)		(21,568,767	)
Investing activities
Purchase of intangible assets, property and equipment				(45,919	)		(25,673	)
Purchase of current and non-current financial assets				(2,115,712	)		(35,514,042	)
Proceeds from sale of current financial assets				21,154,151			28,288,912
Net cash from / (used in) investing activities				18,992,521			(7,250,803	)
Financing activities
Proceeds from issuance of ordinary shares				127,442,651			16,143,686
Proceeds from pre-funded warrants				—			12,915,909
Transaction costs from issuance of ordinary shares and pre-funded warrants				(8,185,666	)		(1,949,998	)
Proceeds from exercise of share options				112,766			—
Repayment of lease liabilities				(151,530	)		(199,904	)
Net cash from / (used in) financing activities				119,218,221			26,909,693
Net increase/decrease in cash and cash equivalents				128,246,517			(1,909,878	)
Effect of exchange rate changes on cash and cash equivalents				2,299,207			(3,462,651	)
Cash and cash equivalents at beginning of period				16,022,171			18,375,979
Cash and cash equivalents at end of period		13		146,567,894			13,003,450

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-6

InflaRx N.V. and subsidiaries

Notes to the unaudited condensed consolidated financial statements

Summary of significant accounting policies and other disclosures

Reporting entity and the Group’s structure

InflaRx N.V. (the “Company” or “InflaRx”) is a Dutch public company with limited liability (naamloze vennootschap) with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce Business Register under CCI number 68904312. The Company’s registered office is at Winzerlaer Straße 2 in 07745 Jena, Germany. Since November 10, 2017, InflaRx N.V.’s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system by applying its proprietary anti-C5a/C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. These consolidated financial statements of InflaRx comprise the Group.

Basis of preparation

These interim condensed consolidated financial statements for the six-month periods ended June 30, 2026 and 2025 have been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include all of the information and disclosures required in the annual financial statements. The condensed consolidated financial statements require management to make judgments, estimates and assumptions that are the same as at year-end. Estimates and underlying assumptions are reviewed on an ongoing basis. Accordingly, this report is to be read in conjunction with the financial statements in the Company’s annual report for the year ended December 31, 2025, on Form 20–F.

The Group’s primary sources of funds are proceeds from the sale of its shares including the initial public offering, following offerings and government grants.

The interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the “Board of Directors”) on August 5, 2026.

The financial statements are presented in euros (€). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar.

All financial information presented in euros has been rounded to the nearest euro. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them or may deviate from other tables.

The accounting policies adopted are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2025, except for the adoption of new standards effective as of January 1, 2026, as set out below. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

The following amendments were adopted effective January 1, 2026, and do not have a material impact on the consolidated financial statements of the Group:

•

Amendments to IAS 21 Effects of Changes in Foreign Exchange Rates: Lack of exchangeability

The following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group’s consolidated financial statements is being assessed:

•

Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, Classification and Measurement of Financial Instruments

•

Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, Contracts Referencing Nature-dependent Electricity

•

IFRS 18 Presentation and Disclosure in Financial Statements

F-7

•

Annual Improvements Volume 11

Revenues

For the three and six months ended June 30, 2026, the Company realized no revenues due to the discontinuation of sales activities in the United States.

For the three and six months ended June 30, 2025, the Company realized revenues from product sales of GOHIBIC (vilobelimab) in the amount of €39.4 thousand.

Cost of sales

During the three and six months ended June 30, 2026, the Group did not incur any cost of sales.

For the three and six months ended June 30, 2025, the Company’s cost of sales amounted to €2.4 million for both periods. Cost of sales primarily includes write-downs of unfinished goods held in inventory that exceed expected sales quantities and are likely to expire before they can be sold.

Sales and marketing expenses

During the three months ended June 30, 2026, the Group incurred €30.2 thousand of sales and marketing expenses in the United States. During the six months ended June 30, 2026, the Group incurred €138.2 thousand of sales and marketing expenses in the United States.

During the three and six months ended June 30, 2025, the Group incurred €1.0 million and €2.5 million of sales and marketing expenses in the United States, respectively.

This decrease is attributable to the discontinuation of sales activities at the end of 2025. The expenses during the three and six months ended June 30, 2026 relate to processing costs associated with closing down sales operations.

Research and development expenses

During the three months ended June 30, 2026, the Group incurred €4.7 million (2025: €7.2 million) of research and development expenses. These expenses are mainly composed of €2.0 million (2025: €2.3 million) in personnel costs due to lower share-based payment expense and €2.3 million (2025: €4.4 million) in external services for the Group’s research and development projects.

During the six months ended June 30, 2026 the Group incurred €8.9 million (2025: €14.2 million) of research and development expenses. These expenses are mainly composed of €4.0 million (2025: €5.0 million) in personnel costs due to lower share-based payment expenses and €4.2 million (2025: €8.4 million) in external services for the Group’s research and development projects.

General and administrative expenses

During the three months ended June 30, 2026, the Group incurred €2.5 million (2025: €3.3 million) of general and administrative expenses. These expenses are mainly composed of €1.4 million (2025: €1.7 million) in personnel costs due to lower share-based payment expenses, €0.5 million (2025: €0.8 million) in legal, consulting and audit fees, and €0.6 million (2025: €0.8 million) in other general and administrative expenses.

During the six months ended June 30, 2026, the Group incurred €5.7 million (2025: €8.3 million) of general and administrative expenses. These expenses are mainly composed of €3.2 million (2025: €4.3 million) in personnel costs due to lower share-based payment expenses, €1.1 million (2025: €2.4 million) in legal, consulting and audit fees, and €1.4 million (2025: €1.6 million) in other general and administrative expenses.

Other income

Other income for the three months ended June 30, 2026 amounted to €0.3 million (2025: €0.9 million). For the six months ended June 30, 2026 other income amounted to €0.5 million (2025: €1.5 million), and primarily relates to research allowances recognized in connection with eligible research and development expenditures incurred during the period.

F-8

Net financial result

	For the three months ended June 30,						For the six months ended June 30,
	2026 (unaudited)			2025 (unaudited)			2026 (unaudited)			2025 (unaudited)
				(in €)

Interest income		770,661			522,221			1,105,429			1,015,985
Interest expenses		(105	)		(323	)		(105	)		(766	)
Interest on lease liabilities		(14,538	)		(3,032	)		(29,347	)		(6,675	)
Financial result		756,017			518,866			1,075,976			1,008,545

Foreign exchange income		4,510,209			1,892,850			5,274,991			3,121,858
Foreign exchange expense		(951,290	)		(4,762,833	)		(1,223,690	)		(7,900,671	)
Foreign exchange result		3,558,919			(2,869,983	)		4,051,301			(4,778,812	)

Result from the revaluation of pre-funded warrants at fair value		(7,912,375	)		852,834			(7,109,214	)		6,963,097
Other financial result		(7,912,375	)		852,834			(7,109,214	)		6,963,097
Net financial result		(3,597,439	)		(1,498,284	)		(1,981,937	)		3,192,829

For the three months ended June 30, 2026, the net financial result decreased by €2.1 million to a loss of €3.6 million, compared with a loss of €1.5 million for the three months ended June 30, 2025. The decrease is mainly attributable to an €8.8 million higher fair value adjustment of pre-funded warrants issued in February 2025, partially offset by a €6.4 million improvement in foreign exchange results due to the short-term strength of the U.S. dollar.

For the six months ended June 30, 2026, the net financial result decreased by €5.2 million to a loss of €2.0 million compared with a gain of €3.2 million for the six months ended June 30, 2025. The decrease is mainly attributable to a €14.1 million higher fair value adjustment of pre-funded warrants issued in February 2025, partially offset by an €8.8 million improvement in foreign exchange results due to the short-term strength of the U.S. dollar.

Other assets

	As of June 30, 2026 (unaudited)		As of December 31, 2025
	(in €)
Non-current other assets
Prepaid expenses		126,201		151,198
Total non-current other assets		126,201		151,198
Current other assets
Prepayments on research & development projects		1,425,993		2,222,380
Prepaid expenses		681,256		923,832
Others		224,719		114,826
Total current other assets		2,331,968		3,261,038
Other assets from research allowances
Current other assets from research allowances		2,997,282		2,487,763
Total other assets from research allowances		2,997,282		2,487,763
Total other assets		5,455,452		5,899,999

F-9

As of June 30, 2026, prepayments on research and development projects amounted to €1.4 million compared to €2.2 million as of December 31, 2025, and consist of prepayments on CRO contracts.

Prepaid expenses consist mainly of prepaid D&O insurance expense for the year 2026, which will be recognized into general and administrative expenses pro rata over the year.

As of June 30, 2026, other assets from research allowances were €3.0 million compared to €2.5 million as of December 31, 2025, which represents reimbursements the Company qualifies for under the German Research Allowance Act (government grant). The increase is due to additional receivables recognized for eligible expenses incurred in the six months ended June 30, 2026 in the amount of €0.5 million.

10.

Tax receivables

As of June 30, 2026, tax receivables amounted to €1.6 million (VAT: €0.2 million,

income tax receivables: €1.3 million) compared to €1.4 million (VAT: €0.3 million, income tax receivables: €1.1 million) as of December 31, 2025.

11.

Financial assets and financial liabilities

Set out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of June 30, 2026 and December 31, 2025:

	As of June 30, 2026 (unaudited)		As of December 31, 2025
	(in €)
Financial assets at amortized cost
Non-current financial assets		237,020		237,373
Thereof marketable securities		—		—
Current financial assets		11,946,598		30,435,088
Thereof marketable securities		11,821,967		30,211,169
Financial liabilities at amortized cost
Trade and other payables		5,517,856		5,608,204
Financial liabilities at fair value
Current liabilities to warrant holders		13,270,142		5,802,128

In February 2025, the Company issued 6,750,000 pre-funded warrants to certain investors in the context of a public offering of securities. As of June 30, 2026, the fair value of the warrants amounted to €13.3 million (Level 1).

As of June 30, 2026, the fair value of current and non-current financial assets (primarily quoted debt securities) amounted to €12.2 million (as of December 31, 2025: €33.5 million) (Level 1). The Group’s debt instruments at amortized cost consist solely of quoted securities that are graded highly by credit rating agencies such as S&P Global and, therefore, are considered low credit risk investments.

As of June 30, 2026, current and non-current financial assets decreased by €18.5 million to €12.2 million compared to €30.7 million as of December 31, 2025. The decrease is mainly due to the financing of day-to-day operations. As of June 30, 2026, trade and other payables decreased by €0.1 million to €5.5 million compared to €5.6 million as of December 31, 2025. As of December 31, 2025, the Company temporarily had higher trade payables from CROs.

F-10

12.

Trade payables and other accrued liabilities

	As of June 30, 2026 (unaudited)		As of December 31, 2025
	(in €)

Accrued liabilities from R&D projects		3,347,873		3,424,362
Accrued liabilities from commercial activities		—		8,000
Accounts payable		832,885		972,383
Other accrued liabilities and payables		1,495,380		1,353,593
Total		5,676,137		5,758,338

Accrued liabilities from R&D projects include third-party services from the Company’s ongoing R&D projects that have not yet been invoiced to the Company as of the reporting date.

13.

Cash and cash equivalents

	As of June 30, 2026 (unaudited)		As of December 31, 2025
	(in €)
Short-term deposits
Money market funds held in U.S. dollars		16,709,150		—
Money market funds held in euros		2,402,588		—
Bank-deposits held in U.S. dollars		93,202,839		7,510,452
Bank-deposits held in euros		29,900,000		7,235,080
Total		142,214,577		14,745,532
Cash at banks
Cash held in U.S. dollars		3,525,223		843,915
Cash held in euros		828,094		432,724
Total		4,353,317		1,276,639
Total cash and cash equivalents		146,567,894		16,022,171

As of June 30, 2026, cash and cash equivalents increased by €130.5 million to €146.6 million compared to €16.0 million as of December 31, 2025, as a result of a registered direct offering of 75,000,000 ordinary shares at an offering price of $2.00 per ordinary share and net proceeds of €119.3 million ($140.4 million) in May 2026.

In mid-June, the Company purchased money market funds. These funds are highly liquid, readily convertible into known amounts of cash at any time, and are subject to an insignificant risk of changes in value. Consequently, the investments meet the criteria for classification as cash equivalents and are therefore presented as cash and cash equivalents by the Company.

14.

Equity

On June 30, 2023, the Company filed a registration statement on Form F-3, or the 2023 Registration Statement, with the Securities and Exchange Commission, or the SEC, with respect to the offer and sale of securities of the Company, which became effective on July 11, 2023. The aggregate initial offering price of the securities that the Company could offer and sell under the related prospectus was not to exceed $250.0 million. In 2024, the Company subsequently filed a prospectus supplement with the SEC relating to an at-the-market program providing for the sale of up to $75.0 million of our ordinary shares over time pursuant to a sales agreement with Leerink Partners LLC, or the Sales Agreement. The 2023 Registration Statement expired on July 11, 2026, and no further sales may be made under the 2023 Registration Statement or the related at-the-market prospectus supplement after that date.

F-11

We did not issue any ordinary shares under the at-the-market program during the six months ended June 30, 2026. As of June 30, 2026, before the expiration of the 2023 Registration Statement, the remaining value authorized for sale under the Sales Agreement amounted to $65.7 million. In May 2026, the Company completed an underwritten registered direct offering of 75,000,000 ordinary shares at an offering price of $2.00 per ordinary share. Net proceeds from the offering were €119.3 million ($140.4 million).

During the six months ended June 30, 2026, 75,362 shares (six months ended June 30, 2025: 0) were issued upon the exercise of share options, resulting in proceeds to the Company in the amount of €112.8 thousand ($132.3 thousand) (six months ended June 30, 2025: 0). All share options exercised during the six months ended June 30, 2026 were granted under the 2017 LTIP.

15.

Share-based payments

Equity settled share-based payment arrangements

InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. at the time of its IPO in November 2017:

Number of share options	2026		2025
Outstanding as of January 1,		148,433		148,433
Exercised during the three months ended June 30,		—		—
Outstanding as of June 30,		148,433		148,433
thereof vested / exercisable		148,433		148,433

Under the terms and conditions of the share option plan 2016, InflaRx GmbH granted rights to subscribe for InflaRx GmbH’s ordinary shares to directors, senior management, and key employees. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. at the time of its IPO in November 2017:

Number of share options	2026		2025
Outstanding as of January 1,		888,632		888,632
Exercised during the six months ended June 30,		—		—
Outstanding as of June 30,		888,632		888,632
thereof vested / exercisable		888,632		888,632

InflaRx also granted share options under the 2017 Long-Term Incentive Plan, or 2017 LTIP, subsequently to its IPO in November 2017. The total number of share options granted during the six months ended June 30, 2026 under the 2017 LTIP was as follows:

Number of share options	2026			2025
Outstanding as of January 1,		11,122,320			8,905,446
Granted during the six months ended June 30,		2,848,925			2,452,000
Exercised during the six months ended June 30,		(75,362	)		—
Expired during the six months ended June 30,		(20,000	)		—
Forfeited during the six months ended June 30,		(25,000	)		(110,500	)
Outstanding as of June 30,		13,850,883			11,246,946
thereof vested / exercisable		11,582,451			9,375,196

F-12

The key information and assumptions related to share options granted during the six months ended June 30, 2026 under the 2017 LTIP were as follows:

Share options granted 2026	Number	Fair value per option	FX rate as of grant date	Fair value per option	Share price at grant date / Exercise price	Expected volatility	Expected life (midpoint based)	Risk-free rate (interpola ted,U.S. sovereign strips curve)

January 06	2,373,975	$0.930	0.8542	0.790 €	$1.17	1.02	5.50	3.772%
January 06	454,950	$0.796	0.8542	0.680 €	$1.17	1.02	5.49	3.771%
May 29	20,000	$1.847	0.8588	1.586 €	$2.40	1.03	5.50	4.165%
	2,848,925

Of the 2,848,925 options granted in the six months ended June 30, 2026 (ended June 30, 2025: 2,452,000), 2,136,450 options (June 30, 2025: 1,700,000) were granted to members of the executive management or Board of Directors. From these options 454,950 options were granted as performance options (ended June 30, 2025: 0). The awards are subject to two independent performance conditions, each covering 50% of the grant. The funding condition is a non-market condition valued using Black-Scholes, with expected vesting adjusted for probability. The share price condition is a market condition valued using a Monte Carlo simulation, with the probability embedded in fair value. Each tranche vests separately, with cliff vesting on December 31, 2026.

Expected dividends are nil for all share options listed above.

Share-based payment expense recognized

For the six months ended June 30, 2026, the Company recognized €1.5 million of share-based payment expense in the statements of operations and comprehensive loss.

For the six months ended June 30, 2025, the Company recognized €3.6 million of share-based payment expense in the statements of operations and comprehensive loss, including €356 thousand for the extension of certain option terms from eight years to ten years.

None of the share-based payment awards were dilutive in determining earnings per share due to the Group’s loss position.

For the three months ended June 30, 2026, the Company recognized €0.6 million (2025: €1.1 million) of share-based payment expense in the statements of operations and comprehensive loss.

Share options exercised

16.

Protective foundation

According to the articles of association of the Company as approved by the annual general meeting in April 2026, up to 180,730,000 ordinary shares and up to 180,730,000 preferred shares with a nominal value of €0.12 per share are authorized to be issued. All shares are registered shares. No share certificates shall be issued.

In order to deter acquisition bids, the Company’s general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation, to exercise a call option pursuant to the call option agreement, upon which preferred shares will be issued by the Company to the protective foundation of up to 100% of the Company’s issued capital held by persons other than the protective foundation, minus one share. The protective foundation is expected to enter into a finance arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation may request the Company to provide, or cause the Company’s subsidiaries to provide, sufficient funding to the protective foundation to enable it to satisfy its payment obligation under the call option agreement.

F-13

These preferred shares will have both a liquidation and dividend preference over the Company’s ordinary shares and will accrue cash dividends at a pre-determined rate. The protective foundation would be expected to require the Company to cancel its preferred shares once the perceived threat to the Company and its stakeholders has been removed or sufficiently mitigated or neutralized. The Company believes that the call option does not represent a significant fair value based on a level 3 valuation since the preferred shares are restricted in use and can be cancelled by the Company.

During the six months ended June 30, 2026, the Company expensed €22.5 thousand (2025: €30.0 thousand) of ongoing costs to reimburse expenses incurred by the protective foundation.

F-14

EX-99.2 3 ef20079015_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes thereto, for the six months ended June 30, 2026 and 2025, respectively, included as Exhibit 99.1 to the report on Form 6-K to which this discussion is attached as Exhibit 99.2. We also recommend that you read our “ITEM 5. Operating and financial review and prospects” and our audited consolidated financial statements for fiscal year 2025, and the notes thereto, which appear in our annual report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, or the SEC, on March 20, 2026. In addition, we recommend that you read any public announcements made by InflaRx N.V.

The following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting principles in the United States and other jurisdictions. We maintain our books and records in euros. Unless otherwise indicated, all references to currency amounts in this discussion are in euros. We have made rounding adjustments to some of the figures included in this discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be arithmetic aggregations of the figures that precede them.

The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under “ITEM 3. Key Information––Risk factors” in the annual report and risks described in our subsequent SEC filings.

Unless otherwise indicated or the context otherwise requires, all references to “InflaRx” or the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V. and its subsidiaries InflaRx GmbH and InflaRx Pharmaceuticals, Inc.

Overview

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. InflaRx is focusing the development of izicopan toward the treatment of AAV and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

Anti-C5aR inhibitor izicopan

To explore the full potential of our anti-C5a/C5aR technologies, we are clinically developing our lead product candidate, izicopan, which is an orally administered, small-molecule inhibitor of C5aR1, for the treatment of ANCA-associated vasculitis, or AAV, a life-threatening kidney disorder, and additional renal diseases. Based on its mode of action and encouraging preclinical and clinical data generated to date, we believe izicopan is a promising product candidate for further development in several disease areas of inflammation, where orally available therapeutics are not available or do not meet the medical need.

Izicopan has shown potential for differentiated characteristics compared to the only marketed C5aR inhibitor, avacopan, in pre-clinical studies and in clinical pharmacology studies. Izicopan has demonstrated higher plasma exposure in animals, including non-human primates, and humans. Izicopan is also characterized by an improved inhibitory activity in a hamster neutropenia model compared to avacopan and in our completed pharmacodynamic Phase 1 studies. As announced in April 2026, in vitro findings demonstrate that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions and liver toxicity. Pre-clinical data have also demonstrated lower reactive metabolite formation of izicopan in human liver microsomes versus the marketed comparator, avacopan. In addition, izicopan demonstrated potential for anti-inflammatory therapeutic effects in several preclinical disease models. In January 2024, InflaRx announced positive results of a single and multiple ascending dose study with izicopan in healthy volunteers. In November 2025, positive data from a Phase 2a clinical study in HS and CSU patients were reported.

F-1

Izicopan for the treatment of AAV and renal disease

On May 6, 2026, concurrent with the pricing of a $150 million underwritten offering of ordinary shares, InflaRx announced it intends to develop izicopan in AAV. Phase 2 trial planning for izicopan in AAV continues as planned, with trial initiation anticipated by late 2026 or early 2027, as previously disclosed. Following the recommendation by the EMA’s Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for avacopan (trade name Tavneos^®) in the European Union, the Company is assessing the feasibility of broadening the development and registrational strategy for AAV in Europe and intends to engage with the EMA regarding both vilobelimab and izicopan as part of its overall development goal to determine the most efficient development pathway to bring the C5a/C5aR inhibition mechanism to patients.

In addition, the Company announced its goal of establishing proof of concept for izicopan across a broader range of complement-mediated life-threatening kidney diseases, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN) and C3 glomerulopathy (C3G).

Izicopan for the treatment of HS and CSU

In a Phase 2a study, izicopan appeared highly active in HS, with improvements in efficacy measures largely differentiated from historically reported placebo response rates, and in line with reported improvements at the 4-week time point for therapies which have successfully completed Phase 3 trials or received approval. Overall, the data suggest an emerging biologic-like clinical profile, with rapid, consistent and significant reductions in all lesion counts, total inflammatory burden (TIB), and patient reported outcomes (in particular NRS30 Skin Pain). InflaRx has largely concluded interactions with FDA regarding an optimized clinical development program for izicopan in HS, and believes a viable path forward exists. The Company believes HS remains a significant opportunity for izicopan, with a market potential that could exceed $1.5 billion per year, with further development currently envisioned only in collaboration with a partner.

In a Phase 2a study, izicopan appeared to demonstrate encouraging activity in CSU, suggesting activity not only differentiated from reported historical placebo rates, but potentially within the range of currently approved therapies. These data further indicate that response rates may deepen with longer-term treatment. InflaRx anticipates that further development in CSU would be conducted only in collaboration with a partner.

F-2

Anti-C5a antibody vilobelimab

Vilobelimab, is a novel, intravenously delivered, first-in-class monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. We have been developing vilobelimab in a wide array of complement-mediated diseases with significant unmet medical need.

Vilobelimab and anti-C5a therapy for the treatment of AAV

On June 30, 2026 InflaRx announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The Company initiated this assessment given the recommendation of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for Tavneos in the European Union, announced on June 26, 2026. The Company announced it intends to engage with EMA regarding both its anti-C5a antibody vilobelimab, which is approved under exceptional circumstances as GOHIBIC in Europe for SARS-CoV-2-induced acute respiratory distress syndrome, and its next-generation oral C5aR inhibitor izicopan. This will be part of the Company’s overall development goal to determine the most efficient development pathway to bring the C5a/C5aR inhibition mechanism to patients.

A growing body of clinical data supporting the utility and safety of anti-C5a therapy in AAV has emerged in recent years. Vilobelimab has been evaluated in two controlled Phase 2 AAV studies, the European IXCHANGE trial (NCT03895801) and the U.S. IXPLORE trial (NCT03712345). In IXCHANGE, which tested vilobelimab as a replacement for glucocorticoids on a background of standard-of-care rituximab or cyclophosphamide, clinical response and remission rates with vilobelimab were comparable to those achieved with standard-dose glucocorticoids, while cumulative glucocorticoid exposure and glucocorticoid-related toxicity were substantially lower in vilobelimab-treated patients. In IXPLORE, vilobelimab added to standard of care was well tolerated without signals of safety concerns. Across both IXCHANGE and IXPLORE, vilobelimab demonstrated a favorable safety and tolerability profile, with IXCHANGE supporting its potential to induce remission while markedly reducing the glucocorticoid burden. In addition, under a license agreement where it holds development and commercialization rights in China, our collaborator Staidson has generated promising AAV data with BDB-001, an anti-C5a antibody produced using the vilobelimab cell line. The multicenter, randomized, open-label, parallel-controlled Phase 1/2 clinical trial by Staidson demonstrated that BDB-001 injection combined with reduced-dose glucocorticoids or without glucocorticoids achieved comparable partial response rates and numerically higher complete response rates at 12 weeks of treatment compared with standard of care using the Birmingham vasculitis score (BVAS). After successful completion of this Phase 1/2 study, Staidson initiated a Phase 3 trial in China in 2025, which is ongoing.

Vilobelimab for the treatment of severe COVID-19

Based on a successfully completed Phase 3 trial demonstrating a 24% reduction in all-cause mortality, in April 2023, InflaRx was granted an EUA by the FDA for the treatment of critically ill, invasively mechanically ventilated COVID-19 patients with vilobelimab. In January 2025, InflaRx also obtained a marketing authorization under exceptional circumstances, from the European Commission for the treatment of adult patients with SARS-CoV-2-induced ARDS, who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation, or IMV, with or without extracorporeal membrane oxygenation, or ECMO. The product has been introduced into the pharmaceutical market in the United States under the tradename GOHIBIC; and is commercially available for ordering by hospitals. However, in December 2025 InflaRx discontinued its active sales activities, while keeping the product available for ordering. Vilobelimab is also being evaluated in a Phase 2 clinical platform study in broader ARDS, funded by the Biomedical Advanced Research and Development Authority, or BARDA. As of June 30, 2026 we received notice from the FDA regarding termination of the EUA for GOHIBIC. The termination of the EUA will be effective 12 months from the date of publication of the Federal Register notice, i.e., July 1, 2027.

F-3

Anti-C5a antibody IFX002

We are developing IFX002 for the treatment of chronic inflammatory diseases. IFX002 is a highly potent anti-C5a antibody, which binds to the same domain of the C5a protein as vilobelimab, but which has a higher humanization grade and altered pharmacokinetic properties compared to vilobelimab. IFX002 is currently in preclinical development. We consider IFX002 to be a life-cycle management product to vilobelimab, given the long remaining patent life of IFX002.

Financial highlights

In May 2026, the Company completed an underwritten registered direct offering of 75,000,000 ordinary shares at an offering price of $2.00 per ordinary share. Net proceeds from the offering were €119.3 million ($140.4 million).

As of June 30, 2026, we had available funds amounting to €158.4 million, composed of €146.6 million in cash and cash equivalents and €11.8 million in marketable securities. Of the €146.6 million cash and cash equivalents, €33.1 million are held in euros and €113.4 million are held in U.S. dollars. Marketable securities held in U.S. dollars have a nominal value of $13.5 million (€11.8 million). We believe that our current funds on hand will be sufficient to fund our planned operations into the end of 2029.

On May 6, 2026, concurrent with the pricing of a $150 million underwritten offering of ordinary shares, InflaRx announced it intends to develop izicopan in AAV. Phase 2 planning for izicopan in AAV continues as planned and uninterrupted across multiple geographies, with trial initiation anticipated by late 2026 or early 2027, as previously disclosed. The Company is assessing the feasibility of multiple development approaches, including the potential for an expedited path to the market in both the United States and Europe, in an effort to best address the evolving regulatory environment surrounding the currently approved comparator, avacopan. In addition, the Company announced its goal of establishing rapid proof of concept for izicopan across a broader range of complement-mediated life-threatening kidney diseases, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN) and C3 glomerulopathy (C3G).

We anticipate that our expenses might increase if and as we:

•

continue research, preclinical and clinical development efforts, as applicable, for any existing and future product candidates, including izicopan, vilobelimab and IFX002;

•

actively seek to identify additional research programs and additional product candidates;

•

seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;

•

establish and expand sales, marketing, distribution and other commercial infrastructure now and in the future to commercialize various products for which we may obtain marketing authorization or approval, if any;

•

require the scale-up and validation of the manufacturing process and the manufacturing of larger quantities of product candidates for clinical development and, potentially, commercialization;

•

collaborate with strategic partners to optimize the manufacturing process for izicopan, vilobelimab, IFX002, and other pipeline products;

•

maintain, expand and protect our intellectual property portfolio;

•

hire and retain additional personnel, such as commercial, marketing, clinical, quality control and scientific personnel; and

•

add operational, financial and management information systems and personnel, including personnel to support our product development as well as commercialization and help us comply with our obligations as a public company.

F-4

Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or any future collaborator is, able to obtain full marketing authorization or approval for, and successfully commercialize, one or more of our product candidates. Successful commercialization will require achievement of key milestones, including completing clinical trials of izicopan, vilobelimab, and any other product candidates, obtaining marketing authorization or approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain marketing authorization or approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of revenues, and if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenue that is large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. In order to succeed, we will need to transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.

Accordingly, we may seek to further fund our operations through public or private equity or debt financings or other sources, including strategic collaborations. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop izicopan, vilobelimab, IFX002 or any additional product candidates.

Our failure to become and remain profitable could depress the market price of our ordinary shares and could impair our ability to raise capital, pay dividends, expand our business, diversify our product offerings or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment.

Research and development expenses

Research and development expenses have consisted principally of:

•

expenses incurred under agreements with CROs, contract manufacturing organizations, or CDMOs, consultants and independent contractors that conduct research and development, preclinical and clinical activities on our behalf;

•

employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization; and

•

professional fees for lawyers related to the protection and maintenance of our intellectual property.

We expense research and development costs as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as status of patient enrollment or clinical site activations for measuring services received and efforts expended. Research and development activities are central to our business model.

Our research and development expenses primarily relate to the following key programs:

•

Izicopan. We are developing izicopan, a product candidate that targets C5aR. We expect to incur additional costs by advancing the clinical and non-clinical development of izicopan. Specifically, we expect to incur expenses during Phase 2 development in AAV and for proof-of-concept studies in additional renal indications. We plan to continue targeting izicopan for complement-mediated, chronic autoimmune and inflammatory conditions where an oral low molecular weight compound might have advantages or is needed for patients and where oral delivery is the medically preferred route of administration.

F-5

•

Vilobelimab. Our expenses associated with vilobelimab have decreased significantly as a result of the January 2026 restructuring and the previous termination of our Phase 3 study in PG. We expect vilobelimab-related expenses to continue to decrease in 2026 compared to 2025. However, we will still incur costs associated with the ongoing participation in the BARDA-sponsored Phase 2 clinical platform study in broader ARDS, maintaining our manufacturing infrastructure for GOHIBIC (vilobelimab) in compliance with regulatory standards, and continued FDA discussions regarding a potential BLA for full approval of GOHIBIC (vilobelimab). We are also assessing the feasibility of broadening the development and registrational strategy of vilobelimab for AAV. Any additional future clinical development activities in PG or other indications would likely be conducted only in collaboration with a partner.

•

IFX002. We are developing IFX002 for the treatment of chronic inflammatory indications. IFX002 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered PK properties compared to vilobelimab and is currently in pre-clinical development. Expenses for this program mainly consist of salaries, costs for preclinical testing conducted by CROs and costs to produce preclinical material.

•

Other development programs. Our other research and development expenses relate to our preclinical studies of other product candidates and discovery activities, expenses for which mainly consist of salaries, costs for production of preclinical compounds and costs paid to CROs.

General and administrative expenses

Our general and administrative expenses consist principally of:

•

employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization;

•

professional fees for auditors and consulting expenses not related to research and development activities;

•

professional fees for lawyers not related to the filing, prosecution, protection and maintenance of our intellectual property;

•

insurance expenses including directors and officers liability insurance premiums; and

•

cost of facilities, travel, communication and office expenses.

F-6

Results of operations

The information below was derived from our unaudited interim condensed consolidated financial statements included elsewhere herein. The discussion below should be read along with these unaudited interim condensed consolidated financial statements and our Annual Report.

Comparison of the three months ended June 30, 2026 and 2025

	three months ended June 30,
	2026			2025			Change
	(in €)
Revenues		—			39,432			(39,432	)
Cost of sales		—			(2,399,583	)		2,399,583
Gross profit		—			(2,360,151	)		2,360,151
Operating expenses
Sales and marketing expenses		(30,175	)		(1,013,347	)		983,172
Research and development expenses		(4,739,126	)		(7,202,942	)		2,463,816
General and administrative expenses		(2,548,319	)		(3,279,485	)		731,166
Total operating expenses		(7,317,619	)		(11,495,775	)		4,178,155
Other income		266,574			937,938			(671,364	)
Other expenses		—			—			—
Operating result		(7,051,045	)		(12,917,988	)		5,866,943
Finance income		770,661			522,221			248,440
Finance expenses		(14,643	)		(3,355	)		(11,288	)
Foreign exchange result		3,558,919			(2,869,983	)		6,428,902
Other financial result		(7,912,375	)		852,834			(8,765,208	)
Income taxes		—			—			—
Income (loss) for the period		(10,648,484	)		(14,416,271	)		3,767,788
Exchange differences on translation of foreign currency		(19,274	)		(113,604	)		94,330
Total comprehensive income (loss)		(10,667,758	)		(14,529,876	)		3,862,118

Revenues

For the three months ended June 30, 2026, we did not generate any revenue (three months ended June 30, 2025: €39.4 thousand). This is attributable to the discontinuation of GOHIBIC (vilobelimab) sales activities in the United States in December 2025.

Cost of sales

	three months ended June 30,
	2026		2025		Change
	(in €)
Cost of sales		—		2,399,583		(2,399,583	)
Total		—		2,399,583		(2,399,583	)

We incurred no cost of sales in the three months ended June 30, 2026 due to the discontinuation of our sales activities in December 2025.

Our cost of sales during the three months ended June 30, 2025 amounted to €2.4 million primarily due to write-downs of unfinished goods on hand exceeding quantities expected to be sold prior to expiry.

F-7

Sales and marketing expenses

	three months ended June 30,
	2026			2025		Change
	(in €)
Third-party expenses		54,440			13,132		41,308
Marketing expenses		—			463,187		(463,187	)
Personnel expenses		(995	)		382,451		(383,446	)
Legal and consulting fees		(24,732	)		105,602		(130,334	)
Other expenses		1,462			48,976		(47,514	)
Total sales and marketing expenses		30,175			1,013,347		(983,172	)

Our sales and marketing expenses incurred for the three months ended June 30, 2026 decreased compared to the three months ended June 30, 2025 by €1.0 million. This decrease is primarily attributable to the discontinuation of our sales activities at the end of 2025.

The expenses of €30.2 thousand during the three months ended June 30, 2026, relate to processing costs associated with closing down sales operations.

Research and development expenses

	three months ended June 30,
	2026		2025		Change
	(in €)
Third-party expenses		2,337,708		4,396,815		(2,059,107	)
thereof vilobelimab		422,119		875,503		(453,384	)
thereof izicopan		1,915,590		3,452,004		(1,536,414	)
thereof non-allocated		—		69,308		(69,308	)
Personnel expenses		1,989,072		2,292,612		(303,540	)
Other expenses		412,345		513,515		(101,169	)
thereof vilobelimab		89,112		201,581		(112,469	)
thereof izicopan		239,816		66,657		173,159
thereof non-allocated		83,419		245,277		(161,858	)
Total research and development expenses		4,739,126		7,202,942		(2,463,816	)

Our research and development expenses incurred for the three months ended June 30, 2026 decreased by €2.5 million to €4.7 million compared to the three months ended June 30, 2025. This decrease is primarily due to lower third-party expenses for external services for the Group’s research and development projects, as well as lower personnel expenses due to reduced share-based payment expenses. The year-over-year decrease in third-party expenses primarily reflects that, during the three months ended June 30, 2025, a wind-down provision following the discontinuation of our PG program in May 2025 was recognized.

The decrease in expenses for vilobelimab is mainly due to the prioritization of our resources on izicopan going forward.

General and administrative expenses

	three months ended June 30,
	2026		2025		Change
	(in €)
Personnel expenses		1,383,885		1,657,678		(273,793	)
Legal, consulting and audit fees		515,423		811,167		(295,744	)
Other expenses		649,011		810,641		(161,630	)
Total general and administrative expenses		2,548,319		3,279,485		(731,166	)

F-8

Our general and administrative expenses incurred for the three months ended June 30, 2026 decreased by €0.7 million to €2.5 million compared to the three months ended June 30, 2025. This decrease is primarily due to lower personnel expenses, including reduced share-based payment expenses and lower legal and consulting fees.

Other income

	three months ended June 30,
	2026		2025		Change
	(in €)
Other income from government grants and research allowances		264,465		919,150		(654,685	)
Further other income		2,109		18,788		(16,679	)
Total other income		266,574		937,938		(671,364	)

Our other income for the three months ended June 30, 2026 decreased by €0.7 million compared to the three months ended June 30, 2025 and primarily consists of research allowances under the “Forschungszulagengesetz” (Research Allowance Act) for the three months ended June 30, 2026.

Net financial result

	three months ended June 30,
	2026			2025			Change
	(in €)
Interest income		770,661			522,221			248,440
Interest expenses		(105	)		(323	)		218
Interest on lease liabilities		(14,538	)		(3,032	)		(11,506	)
Financial Result		756,017			518,866			237,152

Foreign exchange income		4,510,209			1,892,850			2,617,359
Foreign exchange expense		(951,290	)		(4,762,833	)		3,811,543
Foreign exchange result		3,558,919			(2,869,983	)		6,428,902

Result from the revaluation of pre-funded warrants at fair value		(7,912,375	)		852,834			(8,765,208	)
Other financial result		(7,912,375	)		852,834			(8,765,208	)
Net financial result		(3,597,439	)		(1,498,284	)		(2,099,155	)

For the three months ended June 30, 2026, our net financial result decreased by €2.1 million to a loss of €3.6 million from a loss of €1.5 million for the three months ended June 30, 2025. This decrease is mainly attributable to the fair value remeasurement of pre-funded warrants issued in February 2025 in the amount of €7.9 million. In addition, foreign exchange results improved by €6.4 million, driven by the depreciation of the euro against the U.S. dollar.

F-9

18.

Comparison of the six months ended June 30, 2026 and 2025

	six months ended June 30,
	2026			2025			Change
	(in €)
Revenues		—			39,432			(39,432	)
Cost of sales		—			(2,408,874	)		2,408,874
Gross profit		—			(2,369,442	)		2,369,442
Operating expenses
Sales and marketing expenses		(138,247	)		(2,471,326	)		2,333,078
Research and development expenses		(8,909,671	)		(14,219,279	)		5,309,607
General and administrative expenses		(5,725,763	)		(8,342,090	)		2,616,327
Total operating expenses		(14,773,681	)		(25,032,694	)		10,259,013
Other income		514,552			1,479,035			(964,483	)
Other expenses		(66	)		(26	)		(40	)
Operating result		(14,259,195	)		(25,923,127	)		11,663,931
Finance income		1,105,429			1,015,985			89,444
Finance expenses		(29,452	)		(7,441	)		(22,011	)
Foreign exchange result		4,051,301			(4,778,812	)		8,830,113
Other financial result		(7,109,214	)		6,963,097			(14,072,312	)
Income taxes		—			—			—
Income (loss) for the period		(16,241,132	)		(22,730,298	)		6,489,166
Exchange differences on translation of foreign currency		(34,301	)		(264,271	)		229,970
Total comprehensive income (loss)		(16,275,433	)		(22,994,569	)		6,719,136

Revenues

	six months ended June 30,
	2026		2025		Change
	(in €)
Revenues		—		39,432		(39,432	)
Total		—		39,432		(39,432	)

For the six months ended June 30, 2026, we did not generate any revenues from product sales of GOHIBIC (vilobelimab) compared to revenues in the amount of €39 thousand from product sales of GOHIBIC (vilobelimab) in the six months ended June 30, 2025. For 2026, this is attributable to the discontinuation of GOHIBIC (vilobelimab) sales activities in the United States in December 2025.

Revenues reported in the six months ended June 30, 2025 are sales to end customers (hospitals). All revenues are attributed to sales made in the United States.

Cost of sales

	six months ended June 30,
	2026		2025		Change
	(in €)
Cost of sales		—		2,408,874		(2,408,874	)
Total		—		2,408,874		(2,408,874	)

Our cost of sales during the six months ended June 30, 2026 amounted to €0.0 million, attributable to the discontinuation of our sales activities in December 2025.

Our cost of sales during the six months ended June 30, 2025 amounted to €2.4 million primarily due to write-downs of unfinished goods on hand exceeding quantities expected to be sold prior to expiry.

F-10

Sales and marketing expenses

	six months ended June 30,
	2026			2025		Change
	(in €)
Third-party expenses		91,051			220,943		(129,892	)
Marketing expenses		3,082			668,265		(665,183	)
Personnel expenses		53,251			1,026,667		(973,416	)
Legal and consulting fees		(14,577	)		366,934		(381,511	)
Other expenses		5,440			188,517		(183,076	)
Total sales and marketing expenses		138,247			2,471,326		(2,333,078	)

Our sales and marketing expenses incurred for the six months ended June 30, 2026 decreased by €2.3 million compared to the six months ended June 30, 2025 to €0.1 million. This decrease is primarily attributable to the discontinuation of our sales activities at the end of 2025.

Research and development expenses

	six months ended June 30,
	2026		2025		Change
	(in €)
Third-party expenses		4,223,665		8,365,860		(4,142,195	)
thereof vilobelimab		883,678		2,435,412		(1,551,734	)
thereof izicopan		3,249,664		5,792,569		(2,542,905	)
thereof non-allocated		90,323		137,879		(47,556	)
Personnel expenses		3,953,456		4,971,270		(1,017,814	)
Other expenses		732,550		882,149		(149,599	)
thereof vilobelimab		202,933		321,770		(118,837	)
thereof izicopan		413,220		113,024		300,196
thereof non-allocated		116,397		447,355		(330,958	)
Total research and development expenses		8,909,671		14,219,279		(5,309,607	)

Our research and development expenses incurred for the six months ended June 30, 2026 decreased by €5.3 million to €8.9 million compared to the six months ended June 30, 2025. This decrease is primarily due to lower third-party expenses for external services for the Group’s research and development projects, as well as lower personnel expenses due to reduced share-based payment expenses. The year-over-year decrease in third-party expenses primarily reflects that, during the six months ended June 30, 2025, a wind-down provision following the discontinuation of our PG program in May 2025 was recognized.

The decrease in expenses for vilobelimab is mainly due to the prioritization of our resources on izicopan going forward.

General and administrative expenses

	six months ended June 30,
	2026		2025		Change
	(in €)
Personnel expenses		3,212,848		4,286,388		(1,073,540	)
Legal, consulting and audit fees		1,103,952		2,420,129		(1,316,177	)
Other expenses		1,408,963		1,635,573		(226,610	)
Total general and administrative expenses		5,725,763		8,342,090		(2,616,327	)

Our general and administrative expenses incurred for the six months ended June 30, 2026 decreased by €2.6 million to €5.7 million, compared to the six months ended June 30, 2025, mainly due to lower legal, consulting and audit expenses of €1.3 million and lower personnel expenses in the amount of €1.1 million.

F-11

Other income

	six months ended June 30,
	2026		2025		Change
	(in €)
Other income from government grants and research allowances		509,519		1,452,010		(942,490	)
Further other income		5,033		27,026		(21,993	)
Total other income		514,552		1,479,035		(964,483	)

Our other income for the six months ended June 30, 2026 decreased by €1.0 million compared to the six months ended June 30, 2025. Our other income primarily consists of research allowances under the “Forschungszulagengesetz” (Research Allowance Act) in the six months ended June 30, 2026.

Net financial result

	six months ended June 30,
	2026			2025			Change
	(in €)
Interest income		1,105,429			1,015,985			89,444
Interest expenses		(105	)		(766	)		661
Interest on lease liabilities		(29,347	)		(6,675	)		(22,672	)
Financial Result		1,075,976			1,008,544			67,433

Foreign exchange income		5,274,991			3,121,858			2,153,132
Foreign exchange expense		(1,223,690	)		(7,900,671	)		6,676,981
Foreign exchange result		4,051,301			(4,778,812	)		8,830,113

Result of expected credit loss adjustment on marketable securities		—			—			—
Result from the revaluation of pre-funded warrants at fair value		(7,109,214	)		6,963,097			(14,072,312	)
Other financial result		(7,109,214	)		6,963,097			(14,072,312	)
Net financial result		(1,981,937	)		3,192,828			(5,174,766	)

For the six months ended June 30, 2026, net financial result decreased by €5.2 million to a loss of €2.0 million from a gain of €3.2 million. This decrease is mainly attributable to fair value remeasurement effects of pre-funded warrants, issued in February 2025 in the amount of €14.1 million. This effect is partially offset by an €8.8 million improvement in the foreign exchange result.

Liquidity and capital resources

Since inception, we have incurred significant operating losses. For the six months ended June 30, 2026, we incurred a net loss of €16.2 million. To date, we have financed our operations primarily through the sale of our securities. As of June 30, 2026, we had cash and cash equivalents in the amount of €146.6 million and financial assets in the amount of €12.2 million, comprised of marketable securities in the amount of €11.8 million and other financial assets amounting to €0.4 million. Our cash and cash equivalents primarily consist of bank deposit accounts and fixed U.S. dollar term deposits as well as EUR and U.S. dollar money market funds.

F-12

Cash flows

The table below summarizes our consolidated statement of cash flows for the six months ended June 30, 2026 and 2025:

	six months ended June 30,
	2026	2025
	(in €)
Net cash used in operating activities	(9,964,225)	(21,568,767)
Net cash from/ (used in) investing activities	18,992,521	(7,250,803)
Net cash from/ (used in) financing activities	119,218,221	26,909,693
Cash and cash equivalents at the beginning of the period	16,022,171	18,375,979
Effect of Exchange gains/ (losses) on cash and cash equivalents	2,299,207	(3,462,651)
Cash and cash equivalents at the end of the period	146,567,894	13,003,451

Net cash from/used in operating activities

The use of cash in all periods resulted primarily from our net losses, adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities decreased to €10.0 million in the six months ended June 30, 2026, from €21.6 million in the six months ended June 30, 2025.

Net cash from/used in investing activities

Net cash from investing activities increased by €26.2 million in the six months ended June 30, 2026, mainly due to higher proceeds from maturity of marketable securities in the six months ended June 30, 2026 compared to the six months ended June 30, 2025.

Net cash from/used in financing activities

Net cash from financing activities increased by €92.3 million in the six months ended June 30, 2026, compared to the six months ended June 30, 2025, due to a public offering of ordinary shares in the six months ended June 30, 2026.

Funding requirements

We believe our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and capital expenditure requirements under our current business plan through 2029.

We anticipate our expenses will decrease this year with regard to our ongoing activities. In particular, we anticipate significantly reduced sales and marketing efforts for GOHIBIC (vilobelimab) in the United States. We plan to continue Phase 2 planning for izicopan in AAV and continue planning for proof-of-concept studies in additional renal diseases, We are also continuing to conduct required non-clinical studies for izicopan and to conduct a PK bridging study in China. We are also exploring the feasibility of expanding our AAV strategy in Europe to incorporate vilobelimab.

As a result, these events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern and, therefore, the Group may be unable to realize its assets and discharge its liabilities in the normal course of business.

If clinical data is supportive, we may seek marketing approval for any product candidates that we successfully develop. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing sales, marketing, distribution and other commercial infrastructure to commercialize such products. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

Until such time, if ever, that we can generate substantial meaningful product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, royalty-based financings, future collaborations, strategic alliances, licensing arrangements and government grants. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interest of our current shareholders will be diluted, and the terms of these securities may include voting or other rights that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Money received through government grants may require us to provide our product, if approved by regulatory authorities, at unfavorable conditions in such jurisdictions.

F-13

At-the-market program

On June 28, 2024, we entered into a Sales Agreement with Leerink Partners LLC, to sell our ordinary shares from time to time through an at-the-market, or ATM, equity offering program of up to $75.0 million under the 2023 Registration Statement, which expired on July 11, 2026.

We did not issue any ordinary shares under the Sales Agreement in the first six months of 2026.

In 2025, we issued 4,691,149 ordinary shares under the Sales Agreement, resulting in € 6.9 million ($8.0 million) in net proceeds. As of June 30, 2026, before the expiration of the 2023 Registration Statement, the remaining value authorized for sale under the Sales Agreement amounted to $65.7 million. Following expiration of the 2023 Registration Statement on July 11, 2026, no further sales may be made under the 2023 Registration Statement or the related at-the-market prospectus supplement.

For more information as to the risks associated with our future funding needs, see “ITEM 3. Key Information––Risk factors” in our Annual Report.

Underwritten Offering

Share Option Exercises

Off-balance sheet arrangements

As of June 30, 2026, and during the periods presented, we did not have any off-balance sheet arrangements other than as described under “ITEM 5. Operating and financial review and prospects—off-balance sheet arrangements” in our Annual Report.

Contractual obligations and commitments

We do not have any, and during the periods presented we did not have any, contractual obligations and commitments other than as described under “ITEM 5. Operating and Financial Review and Prospects—Liquidity and capital resources––Contractual obligations and commitments” in the Annual Report.

Quantitative and qualitative disclosures about market risk

During the six months ended June 30, 2026, there were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in “ITEM 11. Quantitative and Qualitative Disclosures About Market Risk” in the annual report.

Critical judgments and accounting estimates

There have been no material changes to the significant accounting policies and estimates described in “ITEM 5. Operating and Financial Review and Prospects—Critical judgments and accounting estimates” in the annual report.

Critical accounting estimates

There have been no material changes to the significant accounting policies and estimates described in Note B.2. to our consolidated financial statements in the annual report.

F-14

Cautionary statement regarding forward-looking statements

This discussion contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this discussion and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about the following:

•

the success of our development and registrational strategy for izicopan’s treatment of AAV and other renal diseases, including aHUS, IgAN, and C3G, including our Phase 2 planning in AAV, our assessment of a broader development and registrational strategy in Europe following the recommendation by the EMA’s Committee for Medicinal Products for Human Use to revoke the marketing authorization for Tavneos (avacopan) in the European Union, and our ability to establish proof of concept for izicopan across such indications;

•

the success of our future clinical trials for vilobelimab’s treatment of debilitating or life-threatening inflammatory indications, including ARDS and AAV;

•

potential strategic transactions or collaborations, including a potential partnership of izicopan or vilobelimab for pyoderma gangrenosum, or PG, HS, CSU or any other indications;

•

the timing, progress and results of preclinical studies and clinical trials of vilobelimab, izicopan and any other product candidates, including for the development of vilobelimab or izicopan in several indications including virally induced ARDS, HS, CSU or others, and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally;

•

our interactions with and the receptiveness and approval by regulators regarding the results of clinical trials and potential regulatory approval or authorization pathways, including our intended engagement with the EMA regarding vilobelimab and izicopan;

•

the timing and outcome of any discussions or submission of filings for regulatory approval of vilobelimab, izicopan or any other product candidate, if approved or authorized for commercial use;

•

our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases;

•

our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection;

•

whether the FDA, the EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials;

•

the success of our future clinical trials for vilobelimab, izicopan and any other product candidates and whether such clinical results will reflect results seen in previously conducted preclinical studies and clinical trials;

•

our expectations regarding the size of the patient populations for, the market opportunity for, the medical need for and clinical utility of vilobelimab, izicopan or any other product candidates, if approved or authorized for commercial use;

•

our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of any development candidate in the United States and Europe;

F-15

•

our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;

•

our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved or authorized, any commercial sales;

•

if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory oversight;

•

our ability to comply with enacted and future legislation in seeking marketing approval or authorization and commercialization;

•

our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel;

•

our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any other of our product candidates is being developed or our industry;

•

risks related to our reliance on foreign third-party manufacturers and suppliers, including those located in China; and

•

other risk factors discussed under the “ITEM 3. Key information––Risk factors” section of our Annual Report on Form 20-F.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the “ITEM 3. Key information––Risk factors” section of our Annual Report and risks described in our subsequent SEC filings for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this discussion or in our Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the SEC after the date of this discussion.

F-16

EX-99.3 4 ef20079015_ex99-3.htm EXHIBIT 99.3

Exhibit 99.3

InflaRx Reports Second Quarter 2026 Results and

Highlights Key Achievements and Expected Milestones

•	Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned

•	Initiated feasibility assessment for broadened strategy for AAV in Europe

•	Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR

•	Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof‑of‑concept studies in additional inflammation and immunology (I&I) indications

•	Virtual Capital Markets Day planned for October 8, 2026 in the morning ET

•	Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, including net proceeds from the underwritten public offering completed in May, expected to fund ongoing operations and clinical development through 2029

Jena, Germany, August 6, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced financial results for the three months ended June 30, 2026, and provided a business update.

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “The second quarter was one of major momentum for InflaRx, as we focused on addressing the growing unmet need in ANCA-associated vasculitis, a rare but devastating inflammatory disease. As we track the evolving regulatory environment in AAV, we believe InflaRx is well positioned to bring the important C5a/C5aR inhibition mechanism forward to help patients. We are making substantial progress with Phase 2 planning for izicopan in AAV, while monitoring dynamic regulatory environments in the U.S. and overseas. Our focus remains on bringing novel and much-needed treatment options to patients in AAV and beyond, and we look forward to reporting additional progress in the coming months.”

Select Recent Highlights and Business Update

Progress with izicopan, next-generation oral C5aR inhibitor, and plans for further development

In May 2026, InflaRx announced it intends to develop izicopan in AAV, a rare, life-threatening autoimmune disease characterized by inflammation and damage to small blood vessels, with patients often experiencing renal impairment. Phase 2 planning for izicopan in AAV continues as planned.

The Company also announced it has targeted izicopan development in renal diseases, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN) and C3 glomerulopathy (C3G), where early evidence exists for the role of C5a/C5aR inhibition and where izicopan’s favorable clinical profile could be a significant differentiator. InflaRx is currently in the planning stages for this development effort, with a goal of generating initial data from these open-label proof-of-concept studies in 2027.

Given the evolving regulatory environment surrounding the currently approved C5aR inhibitor, avacopan, InflaRx is evaluating the feasibility of multiple development approaches in AAV, including the potential for an expedited path to the commercial market in both the United States and Europe. Following the recommendation in June of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for Tavneos in the EU, InflaRx announced it intends to engage with EMA regarding vilobelimab and izicopan to evaluate the path to approval in AAV in Europe, with a goal of establishing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patients. Together, vilobelimab and izicopan provide InflaRx with a complementary biologic and oral pipeline that is well positioned to address the evolving treatment landscape and significant unmet medical need in AAV.

In April 2026, InflaRx announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity. Further, in May 2026, the Company announced new pre-clinical data demonstrating lower reactive metabolite formation of izicopan in human liver microsomes versus the marketed comparator, avacopan. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk. While in vitro findings do not directly predict clinical outcomes, InflaRx believes these results support izicopan’s differentiated profile as a potentially best-in-class oral C5a receptor (C5aR) inhibitor.

Furthermore, with the goal of generating proof-of-concept data in additional I&I indications as efficiently as possible, InflaRx intends to initiate a PK bridging study with izicopan in China this year to expedite subsequent proof-of-concept studies in China and elsewhere.

$150 million underwritten offering of ordinary shares

In May, InflaRx announced the pricing of an underwritten registered direct offering of 75,000,000 ordinary shares at an offering price of $2.00 per share. The offering generated net proceeds of €119.3 million ($140.4 million), after deducting underwriting discounts and offering expenses. The Company intends to use the proceeds from the offering to advance its pipeline activities, including development in AAV and select renal diseases, and for working capital and general corporate purposes.

Capital Markets Day

The Capital Markets Day planned for October 8 (morning ET) will feature updates on InflaRx’s development strategy for AAV as well as the potential of izicopan as a best‑in‑class therapy offering differentiated chemistry, metabolic properties, and potential safety advantages. Details regarding the precise timing, the anticipated agenda and speaker line-up are expected by early September.

Dr. Thomas Taapken, Chief Financial Officer of InflaRx, said: “InflaRx is on sound financial footing with a reinforced balance sheet and strongly differentiated pipeline assets. With a sufficient cash runway projected through 2029, we are well positioned to achieve multiple clinical milestones, including initiation of clinical studies with izicopan in AAV and additional renal diseases, as well as their respective data readouts.”

Financial Highlights – 2Q 2026

Sales and marketing expenses

Sales and marketing expenses for the six months ended June 30, 2026, decreased by €2.3 million compared to the six months ended June 30, 2025, to €0.1 million. This decrease is attributable to the discontinuation of our sales activities at the end of 2025.

Research and development expenses

Research and development expenses for the six months ended June 30, 2026, decreased by €5.3 million to €8.9 million compared to the six months ended June 30, 2025, primarily due to lower third-party expenses for external services for the Group’s research and development projects, as well as lower personnel expenses due to reduced share-based payment expenses.

General and administrative expenses

General and administrative expenses decreased by €2.6 million to €5.7 million for the six months ended June 30, 2026, from €8.3 million for the six months ended June 30, 2025. This decrease is primarily due to lower personnel expenses, including reduced share-based payment expenses and lower legal and consulting fees.

Other income

Other income decreased by €1.0 million for the six months ended June 30, 2026, compared to the six months ended June 30, 2025, and primarily consists of research allowances under the “Forschungszulagengesetz” (Research Allowance Act) for the six months ended June 30, 2026.

Net financial result

For the six months ended June 30, 2026, our net financial result decreased by €5.2 million to a loss of €2.0 million from a gain of €3.2 million. This decrease is mainly attributable to fair value remeasurement effects of pre-funded warrants, issued in February 2025 in the amount of €14.1 million. This effect is partially offset by an €8.8 million improvement in the foreign exchange result.

Net loss

For the six months ended June 30, 2026, and 2025, the Company incurred net losses of €16.2 million or €0.17 per ordinary share and €22.7 million or €0.35 per ordinary share, respectively.

Liquidity and capital resources

As of June 30, 2026, total funds available amounted to approximately €158.4 million, comprised of €146.6 million in cash and cash equivalents and €11.8 million in marketable securities.

Net cash used in operating activities

Net cash used in operating activities increased to €10.0 million in the six months ended June 30, 2026, from €21.6 million in the six months ended June 30, 2025.

Net cash from investing activities

Net cash from financing activities

InflaRx N.V. and subsidiaries

Unaudited consolidated statements of operations and comprehensive loss for the six months ended June 30, 2026 and 2025

	For the three months ended June 30,						For the six months ended June 30,
	2026 (unaudited)			2025 (unaudited)			2026 (unaudited)			2025 (unaudited)
	(in €, except for share data)

Revenues		—			39,432			—			39,432
Cost of sales		—			(2,399,583	)		—			(2,408,874	)
Gross profit (loss)		—			(2,360,151	)		—			(2,369,442	)
Sales and marketing expenses		(30,175	)		(1,013,347	)		(138,247	)		(2,471,326	)
Research and development expenses		(4,739,126	)		(7,202,942	)		(8,909,671	)		(14,219,279	)
General and administrative expenses		(2,548,319	)		(3,279,485	)		(5,725,763	)		(8,342,090	)
Other income		266,574			937,938			514,552			1,479,035
Other expenses		—			—			(66	)		(26	)
Operating result		(7,051,045	)		(12,917,988	)		(14,259,195	)		(25,923,127	)
Finance income		770,661			522,221			1,105,429			1,015,985
Finance expenses		(14,643	)		(3,355	)		(29,452	)		(7,441	)
Foreign exchange result		3,558,919			(2,869,983	)		4,051,301			(4,778,812	)
Other financial result		(7,912,375	)		852,834			(7,109,214	)		6,963,097
Income taxes		—			—			—			—
Income (loss) for the period		(10,648,484	)		(14,416,271	)		(16,241,132	)		(22,730,298	)
Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign currency		(19,274	)		(113,604	)		(34,301	)		(264,271	)
Total comprehensive income (loss)		(10,667,758	)		(14,529,876	)		(16,275,433	)		(22,994,569	)

Share information
Weighted average number of shares outstanding		117,663,937			67,747,130			95,103,732			65,542,269
Income (loss) per share (basic/diluted)		(0.09	)		(0.21	)		(0.17	)		(0.35	)

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of financial position as of June 30, 2026 and December 31, 2025

	June 30, 2026 (unaudited)			December 31, 2025
	(in €)
ASSETS
Non-current assets
Property and equipment		267,714			289,317
Right-of-use assets		802,608			861,667
Intangible assets		78,123			42,255
Other assets		126,201			151,198
Financial assets		237,020			237,373
Total non-current assets		1,511,667			1,581,810
Current assets
Current other assets		2,331,968			3,261,038
Other assets from government grants and research allowance		2,997,282			2,487,763
Tax receivables		1,551,922			1,428,428
Financial assets		11,946,598			30,435,088
Cash and cash equivalents		146,567,894			16,022,171
Total current assets		165,395,665			53,634,487
TOTAL ASSETS		166,907,332			55,216,297

EQUITY AND LIABILITIES
Equity
Issued capital		17,684,187			8,675,143
Share premium		465,336,467			354,975,760
Other capital reserves		50,092,973			48,560,500
Accumulated deficit		(394,067,134	)		(377,826,001	)
Other components of equity		7,137,079			7,171,379
Total equity		146,183,572			41,556,781
Non-current liabilities
Lease liabilities		560,494			640,973
Other liabilities		36,877			36,877
Total non-current liabilities		597,371			677,850
Current liabilities
Trade and other payables		5,303,862			5,399,383
Lease liabilities		272,685			256,943
Employee benefits		907,425			1,164,259
Liabilities to warrant holders		13,270,142			5,802,128
Other liabilities		372,275			358,954
Total current liabilities		20,126,389			12,981,666
Total Liabilities		20,723,760			13,659,516
TOTAL EQUITY AND LIABILITIES		166,907,332			55,216,297

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of changes in shareholders’ equity for the six months ended June 30, 2026 and 2025

(in €, except for share data)	Issued capital		Share premium			Other capital reserves		Accumulated deficit			Other components of equity			Total equity
Balance as of January 1, 2026		8,675,143		354,975,760			48,560,500		(377,826,001	)		7,171,379			41,556,781
Loss for the period		—		—			—		(16,241,132	)		—			(16,241,132	)
Exchange differences on translation of foreign currency		—		—			—		—			(34,301	)		(34,301	)
Total comprehensive loss		—		—			—		(16,241,132	)		(34,301	)		(16,275,433	)
Issuance of ordinary shares		9,000,000		118,442,651			—		—			—			127,442,651
Transaction costs for ordinary shares		—		(8,185,666	)		—		—			—			(8,185,666	)
Equity-settled share-based payments		—		—			1,532,473		—			—			1,532,473
Share options exercised		9,043		103,722			—		—			—			112,766
Balance as of June 30, 2026		17,684,186		465,336,467			50,092,973		(394,067,133	)		7,137,078			146,183,572

Balance as of January 1, 2025		7,122,205		334,929,685			44,115,861		(332,192,221	)		7,440,510			61,416,039
Loss for the period		—		—			—		(22,730,298	)		—			(22,730,298	)
Exchange differences on translation of foreign currency		—		—			—		—			(264,271	)		(264,271	)
Total comprehensive loss		—		—			—		(22,730,298	)		(264,271	)		(22,994,569	)
Issuance of ordinary shares		1,007,450		15,136,235			—		—			—			16,143,686
Transaction costs for ordinary shares		—		(1,109,305	)		—		—			—			(1,109,305	)
Equity-settled share-based payments		—		—			3,588,514		—			—			3,588,514
Balance as of June 30, 2025		8,129,656		348,956,615			47,704,375		(354,922,519	)		7,176,239			57,044,364

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025

	For the six months ended June 30,
	2026 (unaudited)			2025 (unaudited)
	(in €)
Operating activities
Loss for the period		(16,241,132	)		(22,730,298	)
Adjustments for:
Depreciation & amortization of property and equipment, right-of-use assets and intangible assets		179,263			228,801
Net finance income		1,981,937			(3,192,828	)
Share-based payment expense		1,532,473			3,588,514
Net foreign exchange differences and other adjustments		1,621,940			1,518,421
Changes in:
Other assets from government grants and research allowances		(509,519	)		(782,175	)
Other assets and trade receivables		830,572			(408,339	)
Employee benefits		(256,834	)		(950,043	)
Other liabilities		13,321			60,068
Trade and other payables		(95,521	)		(1,658,576	)
Inventories		—			1,859,251
Interest received		1,009,374			906,087
Interest paid		(30,100	)		(7,652	)
Net cash used in operating activities		(9,964,225	)		(21,568,767	)
Investing activities
Purchase of intangible assets, property and equipment		(45,919	)		(25,673	)
Purchase of current and non-current financial assets		(2,115,712	)		(35,514,042	)
Proceeds from sale of current financial assets		21,154,151			28,288,912
Net cash from / (used in) investing activities		18,992,521			(7,250,803	)
Financing activities
Proceeds from issuance of ordinary shares		127,442,651			16,143,686
Proceeds from pre-funded warrants		—			12,915,909
Transaction costs from issuance of ordinary shares and pre-funded warrants		(8,185,666	)		(1,949,998	)
Proceeds from exercise of share options		112,766			—
Repayment of lease liabilities		(151,530	)		(199,904	)
Net cash from / (used in) financing activities		119,218,221			26,909,693
Net increase/decrease in cash and cash equivalents		128,246,517			(1,909,878	)
Effect of exchange rate changes on cash and cash equivalents		2,299,207			(3,462,651	)
Cash and cash equivalents at beginning of period		16,022,171			18,375,979
Cash and cash equivalents at end of period		146,567,894			13,003,450

About izicopan

Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7). In addition, InflaRx is planning for development of izicopan in AAV and additional renal indications.

About vilobelimab

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies, vilobelimab has been shown to control the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response. Vilobelimab has been evaluated in two controlled Phase 2 AAV studies, the European IXCHANGE trial and the U.S. IXPLORE trial.

About InflaRx N.V.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

	InflaRx N.V.		MC Services AG
	Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de		Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the success of our future clinical trials for izicopan’s treatment of AAV and other renal diseases, including aHUS, IgAN and C3G, and our ability to establish proof of concept for izicopan across such indications; the timing, progress and results of preclinical studies and clinical trials of vilobelimab, izicopan and any other of our product candidates; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including potential regulatory paths in AAV for vilobelimab and izicopan and related discussions with EMA; the timing and outcome of any discussions or submission of filings for regulatory approval of vilobelimab, izicopan or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval and/or marketing authorization for any indication; potential strategic transactions or collaborations, including a potential partnership of izicopan or vilobelimab for PG; whether the FDA, EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes, the optimization of our manufacturing methods and processes, and our ability to rely on existing third-party manufacturers or engage additional third-party manufacturers for planned future clinical trials and commercial supply; our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved or authorized, any commercial sales; if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory oversight; our ability to comply with enacted and future legislation in seeking marketing approval, authorization or commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any other of our product candidates is being developed or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.